Higher drug exposure in women due to lower renal and hepatic clearance and body composition can increase efficacy but also toxicity, highlighting the need to reassess dosing.
Three medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be deterring patients. Not everyone agrees.
Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...
It can be surprising to learn that lung cancer can develop in people who have never smoked. In fact, up to 20% of lung ...
Popular comedian Jessica Salomon returned to social media this week to update fans on her battle against advanced lung cancer ...
Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and ...
Aging is associated with increased risk for nearly every lung disease, including acute conditions like pneumonia and chronic diseases like chronic obstructive pulmonary disease, idiopathic pulmonary ...
EVERY day without a dedicated PhilHealth Z Benefit Package for lung cancer means more Filipino families face delayed ...
A new Ohio University study offers a glimmer of hope in the fight against lung cancer. Monica Robins has that story and more ...
The past 30 years have seen tremendous progress in our fundamental understanding of lung cancer and the development of new treatment strategies,” senior researcher Dr. Cary Gross, a professor at Yale ...
LIMA — Pulmonologist Dr. Katie Capp warns her patients that cigarette smoke is the leading cause of preventable death ...
The 2023 ACS lung cancer screening guidelines increase eligibility but reduce screening specificity across racial and ethnic subgroups.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results